SuperGen Withdraws Orathecin From EMEA Consideration
This article was originally published in The Pink Sheet Daily
Executive Summary
The European Medicines Agency raises “major concerns” with the pancreatic cancer therapy rubitecan.
You may also be interested in...
SuperGen Orathecin Hits Road Block: Phase III Nixed For Combo Claim In Pancreatic Cancer
Phase II trial fails to meet pre-specified threshold for median survival.
SuperGen Orathecin Hits Road Block: Phase III Nixed For Combo Claim In Pancreatic Cancer
Phase II trial fails to meet pre-specified threshold for median survival.
Supergen Will Pursue Orathecin As Combo Therapy Following NDA Withdrawal
Withdrawal of NDA for second-line treatment of pancreatic cancer is “most prudent course of action,” firm says following talks last week with FDA. Supergen is moving ahead with a combination trial with gemcitabine.